查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1976589

登革热检测市场：依检测方法、技术、最终用户、产品类型、安装位置和检体类型划分－2026-2032年全球预测

Dengue Testing Market by Test Type, Technology, End User, Product Type, Setting, Sample Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，登革热检测市场价值将达到 5.5861 亿美元，到 2026 年将成长至 5.9901 亿美元，到 2032 年将达到 8.5512 亿美元，复合年增长率为 6.27%。

主要市场统计数据
基准年 2025 5.5861亿美元
预计年份：2026年 5.9901亿美元
预测年份 2032 8.5512亿美元
复合年增长率 (%) 6.27%

本文将介绍登革热诊断的现状，包括不断发展的检测方法、实施挑战以及在医疗环境中进行临床判断的必要性。

由于科技的快速发展、医疗服务模式的变革以及公共卫生重点的调整，登革热诊断技术正经历重大变革。儘管准确快速的检测仍然是有效临床管理和疫情控制的基础，但从血清学检测到抗原检测和分子诊断等多种检测方法的存在，给临床医生、实验室技术人员和采购经理带来了复杂的决策环境。这就需要在临床需求、操作限制和监管要求之间进行谨慎的权衡。

平台快速创新、检测分散化以及不断变化的法规正在重塑诊断路径，并加速医疗保健系统采用这些方法。

过去五年标誌着登革热检测的研发、检验和实施方式发生了转折。检测化学和平台工程的进步提高了多种检测方法的分析性能，加快了抗原检测的反应速度，并提高了分子检测的处理能力和自动化程度。同时，数位转型将诊断仪器与实验室资讯系统连接起来，实现了即时报告并整合到监控网路中。由此，一个响应更迅速的诊断生态系统得以构建，从而能够更有效地支持疫情爆发检测和临床分诊。

评估美国于 2025 年实施关税对供应链调整、采购应对措施以及诊断药物采购和营运的策略影响。

美国在2025年实施的新关税为采购登革热诊断组件和成品检测套组的机构带来了复杂的挑战。这些关税措施适用于进口设备、试剂和某些检测套组组件，增加了从受影响地区采购特定产品的直接成本，迫使采购团队重新评估筹资策略和总到岸成本。供应商和医疗系统正在采取措施，透过重新评估供应商组合、探索区域性生产替代方案以及重组分销协议来减轻眼前的成本负担。

基于深度细分的诊断见解，解释了测试类型、技术、最终用户、产品形式、安装环境和检体矩阵如何决定实施方案的选择。

了解细分市场动态对于选择合适的诊断策略和调整产品系列以满足使用者需求至关重要。从检测类型来看，抗体检测、抗原检测和分子检测之间存在明显的临床和操作权衡。抗体检测（分为IgG和IgM检测）在先前接触评估和血清流行病学调查中发挥重要作用。抗原检测（包括NS1酵素免疫分析法和快速NS1检测）凭藉其快速性，有助于早期发现。分子检测，包括常规PCR和即时PCR，仍然是确诊的标准方法，需要高分析灵敏度和基因型资讯。

美洲、欧洲、中东和非洲以及亚太地区的区域诊断重点和实施决定了我们的采购和部署策略。

区域趋势影响诊断方法的优先排序、检验和采购，美洲、欧洲、中东和非洲以及亚太地区的实际情况各不相同。在美洲，由于检查室网路完善且私部门积极参与，以集中式分子检测为照护现场抗原检测的混合模式较为适用。特定国家的法规结构为紧急使用和上市后监测提供了明确的途径，使製造商能够在展示实际应用效能的同时扩大分销范围。

诊断设备製造商如何调整产品系列、製造韧性和数位化能力，以提供综合登革热检测解决方案并确保供应链安全？

登革热诊断生态系统中的主要企业正透过产品开发、策略伙伴关係和对生产韧性的投资，满足不断变化的需求。拥有包括抗原、抗体和分子检测在内的多元化产品组合的企业，能够满足多层次的临床路径需求，在临床现场提供快速筛检检测，并在中心检查室提供确诊检测。检测开发商和仪器製造商之间的策略合作正在加速整合解决方案的交付，从而减轻最终用户检验的负担，并缩短临床部署时间。

为诊断产业领导者提供切实可行的策略步骤，以加强供应链、加速照护现场创新，并透过整合数位连结来推动应用。

产业领导者应迅速调整产品开发、供应链策略和客户参与，以适应登革热诊断领域不断变化的实际情况。首先，应优先考虑采购管道多元化，并探索区域製造伙伴关係，以降低关税造成的成本波动风险，并缩短关键试剂和仪器组件的前置作业时间。投资于灵活的生产合约和双重筹资策略可确保供应连续性，并增强供应商的议价能力。其次，应加快开发并向市场推出与领先品牌相容的照护现场抗原检测和侧向层析检测产品，以满足快速分流和分散式监测的需求，同时保留用于确诊和基因分型的实验室级分子检测方案。

采用严谨的混合方法研究途径，结合专家访谈、检查室检验审查、监管分析和供应链映射，得出以营运为中心的见解。

本研究采用结构化的混合方法整合证据，结合了定性专家访谈、检查室检验审查、监管指南分析以及对同行评审文献和技术白皮书的系统性回顾。主要工作包括透过与临床实验室技术人员、感染疾病专家、采购经理和诊断试剂开发人员对话，收集关于检测性能、操作限制和实施注意事项的实际观点。检查室检验审查检验了抗体、抗原和分子诊断类别中代表性检测的分析灵敏度、特异性和操作特性，重点关注检体基质的适用性和仪器要求。

对诊断技术创新、营运完整性和供应链韧性进行最终综合分析，以确定有效的登革热检测策略和专案优先事项。

技术创新、去中心化和供应链重组的整合，为登革热诊断带来了机会和营运挑战。快速抗原检测和改进的侧向层析检测方法提高了临床及时发现病例的能力。同时，PCR设备和检查室自动化技术的进步，使得集中式确诊检测和基因分型监测仍然不可或缺。此外，贸易政策的变化等外部因素，也使得供应链韧性和筹资策略成为决定采购风险和专案连续性的关键因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 登革热检测市场（依检测类型划分）

  • 抗体检测
    • IgG抗体检测
    • IgM抗体检测
  • 抗原检测
    • Ns1酵素免疫分析法
    • NS1快速侦测
  • 分子检测
    • 常规聚合酵素链锁反应
    • 即时聚合酵素链锁反应

第九章：登革热检测市场：依技术划分

  • 酵素免疫分析法
  • 侧向流动免疫检测
    • 胶体金法
    • 萤光免疫分析
  • 微阵列技术
  • 聚合酵素链锁反应
    • 常规聚合酵素链锁反应
    • 即时聚合酵素链锁反应

第十章：登革热侦测市场：依最终用户划分

  • 诊所
  • 诊断检查室
  • 医院
  • 研究机构

第十一章 登革热检测市场：依产品类型划分

  • 装置
    • 领导者
    • 聚合酵素连锁反应热迴圈仪
  • 软体解决方案
  • 检测套组

第十二章：登革热检测市场（按地区划分）

  • 中心检查室
  • 护理点

第十三章 登革热侦测市场（依检体类型划分）

  • 电浆
  • 血清
  • 全血

第十四章 登革热检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：登革热检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 登革热检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国登革热检测市场

第十八章：中国登革热检测市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Alpine Biomedicals Pvt Ltd.
  • Bio-Rad Laboratories, Inc.
  • Chembio Diagnostics, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Meridian Bioscience, Inc.
  • MNP Meditech Pvt. Ltd.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0E5

The Dengue Testing Market was valued at USD 558.61 million in 2025 and is projected to grow to USD 599.01 million in 2026, with a CAGR of 6.27%, reaching USD 855.12 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 558.61 million
Estimated Year [2026] USD 599.01 million
Forecast Year [2032] USD 855.12 million
CAGR (%) 6.27%

Introducing the current dengue diagnostics environment with evolving assay modalities, deployment challenges, and clinical decision imperatives across care settings

Dengue diagnostic capabilities are at a pivotal juncture, shaped by rapid technological progress, shifting care delivery models, and evolving public health priorities. Accurate and timely detection remains foundational to effective clinical management and outbreak control, while the diversity of available assays-from serology to antigen detection to molecular methods-creates a complex decision environment for clinicians, laboratorians, and procurement leaders. The landscape demands careful calibration between clinical needs, operational constraints, and regulatory expectations.

Historically, laboratory-based molecular platforms provided the highest analytical sensitivity, contrasted with point-of-care antigen assays that emphasized speed and simplicity. However, these distinctions are blurring as innovations in lateral flow chemistry, microarray platforms, and real-time polymerase chain reaction instruments narrow gaps in performance, cost per test, and deployment flexibility. In parallel, the global push toward decentralized testing and stronger surveillance has increased demand for assays validated on a range of sample types including plasma, serum, and whole blood, and for solutions that integrate with electronic health systems to enable case reporting and epidemiological monitoring.

Against this backdrop, stakeholders must balance clinical performance metrics such as sensitivity, specificity, and window-of-detection with pragmatic considerations including throughput, cold-chain requirements, and training needs at clinics and point-of-care settings. As dengue continues to circulate in endemic and newly exposed regions, the capacity to choose and implement diagnostics that align with local laboratory infrastructure and patient pathways will be a defining factor in limiting morbidity and optimizing resource use.

How rapid platform innovation, decentralization of testing, and regulatory evolution are reshaping diagnostic pathways and accelerating adoption across healthcare systems

The past five years have seen transformative shifts that are redefining how dengue testing is developed, validated, and delivered. Advances in assay chemistry and platform engineering have lifted analytical performance across multiple categories, enabling antigen tests with faster time-to-result and molecular tests with greater throughput and automation. These technology improvements are being accompanied by digital transformations that connect diagnostic devices to laboratory information systems, enabling real-time reporting and integration into surveillance networks. The result is a more responsive diagnostic ecosystem that can better support outbreak detection and clinical triage.

Simultaneously, there has been a marked movement toward decentralization of testing. Point-of-care settings and outpatient clinics are increasingly equipped to perform rapid antigen and antibody assays, facilitated by simpler workflows and lower training requirements. This shift is complemented by investments in portable PCR instruments and reader devices that allow molecular-level confirmation closer to the patient. As a consequence, healthcare systems are re-evaluating diagnostic algorithms to balance the use of rapid screening assays with confirmatory molecular testing, optimizing resource allocation while preserving diagnostic confidence.

Market dynamics have also been influenced by new regulatory pathways and emphasis on real-world performance data. Health authorities are leaning on post-market surveillance and conditional approvals that prioritize timely access without sacrificing reliability. In parallel, strategic partnerships among diagnostics manufacturers, academic groups, and public health agencies are accelerating validation studies, enabling faster adoption of innovative assays. Taken together, these changes are driving a more agile, connected, and clinically integrated approach to dengue testing that prioritizes speed, accuracy, and operational fit.

Assessing the 2025 United States tariff-induced supply chain adjustments, procurement responses, and strategic implications for diagnostic sourcing and operations

The introduction of new tariffs in the United States in 2025 has introduced a layer of complexity for organizations procuring dengue diagnostic components and finished assays. Tariff measures applied to imported instruments, reagents, and certain assay components have increased the direct cost of sourcing specific items from affected jurisdictions, prompting procurement teams to re-assess sourcing strategies and total landed cost. Suppliers and health systems have responded by reevaluating supplier portfolios, seeking regional manufacturing alternatives, and restructuring distribution agreements to mitigate immediate cost exposure.

Beyond procurement cost pressures, the tariff environment has influenced supply chain design and inventory management. Organizations with limited domestic supply options have increased safety stock levels and extended planning horizons to buffer against import cost volatility and potential lead-time increases. Suppliers have accelerated efforts to localize production of critical inputs, including readers and thermal cyclers, as well as key consumables and reagents, though such initiatives require capital investment and time to realize. In the interim, some buyers have negotiated longer-term contracts to secure supply at predictable prices, while others have diversified their supplier base to distribute risk.

The tariff-driven reconfiguration has also affected competitive dynamics. Manufacturers with vertically integrated supply chains or local production footprints are gaining relative advantage, as they can offer more stable pricing and shorter lead times. Conversely, smaller suppliers reliant on cross-border sourcing face pressure to justify pricing and demonstrate continuity of supply. Public health programs and hospitals operating under constrained budgets are particularly exposed to these shifts, prompting re-prioritization of procurement toward assays and platforms that deliver the most clinical utility per dollar and that minimize exposure to tariff-affected inputs.

Deep segmentation-driven diagnostic insights describing how test types, technologies, end users, product formats, settings, and sample matrices determine deployment choices

Understanding segmentation dynamics is essential to selecting appropriate diagnostic strategies and aligning product portfolios with user needs. When viewing the landscape through the lens of test type, there are clear clinical and operational trade-offs among antibody, antigen, and molecular options. Antibody testing, split into IgG and IgM assays, serves useful roles in retrospective exposure assessment and seroprevalence work, while antigen testing-comprising NS1 enzyme-linked immunosorbent assays and rapid NS1 tests-supports early detection with the benefit of speed. Molecular testing, including conventional PCR and real-time PCR approaches, remains the standard for confirmation where high analytical sensitivity and genotype information may be required.

Technological segmentation further influences adoption. Enzyme-linked immunosorbent assays continue to underpin high-throughput laboratory operations, whereas lateral flow immunoassays, differentiated by colloidal gold or fluorescent readouts, enable true point-of-care deployment with varying degrees of quantitative capacity. Microarray platforms add multiplexing capabilities that are valuable in differential diagnosis scenarios and in research settings, and polymerase chain reaction technologies, from conventional to real-time formats, provide the backbone for sensitive and specific viral detection that informs clinical decision-making and surveillance.

End-user considerations also drive product selection and implementation strategies. Clinics and point-of-care environments favor rapid, user-friendly formats with minimal instrument dependence; diagnostic laboratories emphasize assay reproducibility and throughput; hospitals balance the need for both rapid triage and confirmatory testing streams; and research institutes require platforms that support methodological flexibility and in-depth analyses. Product type segmentation highlights complementary commercial approaches: instruments and readers, which include thermal cyclers and digital readers, underpin platform-dependent assays; software solutions enable connectivity, data analytics, and results management; and test kits deliver the consumables required for routine testing operations. Finally, setting and sample type choices shape logistics and validation strategies, with central laboratories providing controlled environments that support complex workflows and point-of-care settings necessitating robustness across plasma, serum, and whole blood matrices. An integrated view across these segmentation dimensions reveals where investment in instrumentation, biochemical chemistry, and operational enablement will yield the greatest clinical and commercial returns.

Regional diagnostic priorities and implementation realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape procurement and deployment strategies

Regional dynamics shape how diagnostics are prioritized, validated, and procured, with distinct operational realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory networks and considerable private-sector participation favor a mixed model of centralized molecular testing supplemented by point-of-care antigen testing in outpatient and emergency settings. Regulatory frameworks in certain countries provide clear pathways for emergency use and post-market surveillance, enabling manufacturers to scale distribution while demonstrating real-world performance.

Europe, the Middle East & Africa present a mosaic of adoption patterns influenced by national regulatory regimes and heterogeneous healthcare infrastructures. High-resource markets in Europe emphasize harmonized validation standards and integration with electronic health records, while markets across the Middle East and Africa often grapple with logistical constraints that drive demand for robust, low-maintenance assays and point-of-care platforms that tolerate variable cold-chain conditions. Collaborative procurement mechanisms and donor-supported initiatives play a meaningful role in driving access in lower-resource settings.

Asia-Pacific exhibits strong demand for both high-throughput laboratory solutions in metropolitan centers and rapid diagnostic options for decentralized clinics across endemic regions. Several countries in the region have developed local manufacturing capacity, which influences pricing and supply resiliency. Cross-border collaboration and regional surveillance networks have strengthened, fostering data sharing and harmonized response strategies. Taken together, these regional characteristics underline that diagnostic selection and deployment strategies must be tailored to local infrastructure, regulatory pathways, and epidemiological context to achieve effective case detection and public health impact.

How diagnostics companies are aligning product portfolios, manufacturing resilience, and digital capabilities to deliver integrated dengue testing solutions and secure supply chains

Leading firms and innovators in the dengue diagnostics ecosystem are responding to emergent needs through a combination of product development, strategic partnerships, and investments in manufacturing resilience. Companies with diversified portfolios that span antigen, antibody, and molecular offerings are positioned to meet multi-tiered clinical pathways, providing rapid screening at point-of-care and confirmatory testing in centralized laboratories. Strategic collaborations between assay developers and instrument manufacturers have accelerated the availability of integrated solutions that reduce validation burden for end users and shorten time-to-clinic deployment.

Commercial strategies increasingly emphasize connectivity features and software-enabled services that enhance the utility of diagnostic platforms. Companies that offer readers or thermal cyclers paired with secure data management systems enable laboratories and public health agencies to collect and analyze testing data more efficiently, improving case tracking and resource allocation. In addition, manufacturers that have invested in regional production or established distributed manufacturing partnerships are seeing tangible benefits in terms of supply continuity and responsiveness to tariff- or logistics-driven disruptions.

Innovation is also manifest in go-to-market approaches. Organizations that support end users through training, localized validation support, and bundled service agreements reduce implementation friction and build long-term adoption. Smaller specialized developers contribute to the ecosystem by delivering niche or high-performance assays that can be licensed or co-branded with larger platform providers. Collectively, these corporate behaviors underscore a shift toward integrated solutions that combine assay chemistry, hardware, and digital infrastructure to meet the practical demands of diverse healthcare environments.

Actionable strategic steps for diagnostics leaders to strengthen supply chains, accelerate point-of-care innovation, and integrate digital connectivity to drive adoption

Industry leaders should act decisively to align product development, supply chain strategy, and customer engagement with the evolving realities of dengue diagnostics. First, prioritize diversification of sourcing and consider regional manufacturing partnerships to reduce exposure to tariff-induced cost volatility and to shorten lead times for critical reagents and instrument components. Investing in flexible manufacturing contracts and dual-sourcing strategies will preserve continuity and create negotiating leverage with suppliers. Next, accelerate development and market readiness of point-of-care antigen and lateral flow formats with reader compatibility to meet demand for rapid triage and decentralized surveillance, while maintaining laboratory-grade molecular options for confirmatory testing and genotype analysis.

Leaders must also integrate digital enablement into product roadmaps. Embedding connectivity and standardized data export capabilities within instruments and readers will facilitate real-time case reporting, contribute to public health intelligence, and create value-added service opportunities. Concurrently, focus on end-user enablement by designing simplified workflows, providing comprehensive validation packages, and investing in training programs that reduce adoption friction. From a commercial perspective, offer flexible contracting models that account for procurement cycles in public health programs and hospitals, including outcome-oriented agreements and bundled solutions that combine instruments, consumables, and software services.

Finally, engage proactively with regulators and public health stakeholders to design validation studies that reflect real-world performance, including evaluations across plasma, serum, and whole blood, and in both central laboratory and point-of-care settings. Transparent post-market surveillance and robust real-world evidence generation will build trust and facilitate broader adoption. These combined actions will position companies to capture clinical relevance, maintain supply stability, and drive sustainable growth in an increasingly competitive and fragmented environment.

Rigorous mixed-methods research approach combining expert interviews, laboratory validation reviews, regulatory analyses, and supply chain mapping to produce operationally focused insights

This research synthesizes evidence from a structured, mixed-methods approach that combines qualitative expert interviews, laboratory validation reviews, regulatory guidance analyses, and a systematic review of peer-reviewed literature and technical white papers. Primary engagements included conversations with clinical laboratorians, infectious disease specialists, procurement leads, and diagnostic developers to capture frontline perspectives on assay performance, operational constraints, and deployment considerations. Laboratory validation reviews examined reported analytical sensitivity, specificity, and operational characteristics for representative assays across antibody, antigen, and molecular categories, with attention to sample matrix compatibility and instrument requirements.

Regulatory guidance and policy documents were analyzed to understand approval pathways, emergency use provisions, and post-market surveillance expectations that influence time-to-adoption. The methodology also incorporated supply chain mapping to identify sourcing dependencies for instruments, consumables, and reagents, and to assess potential exposure to tariff and logistics disruptions. Where possible, findings were triangulated across data streams to increase confidence in conclusions and to highlight areas where evidence is limited or variable.

Limitations inherent to the methodology include variability in the quality and availability of performance data across assay types and the rapidly evolving nature of regulatory decisions and supply chain conditions. To mitigate these limitations, the research prioritized primary stakeholder input and validated laboratory findings against multiple independent sources. The resulting analysis aims to provide an operationally useful synthesis rather than definitive technical validation, supporting decision-makers in planning implementation and procurement strategies that account for both clinical and logistical considerations.

Concluding synthesis of diagnostic innovation, operational alignment, and supply chain resilience that defines effective dengue testing strategies and program priorities

The convergence of technological innovation, decentralization, and supply chain realignment has created both opportunities and operational challenges for dengue diagnostics. Rapid antigen and improved lateral flow formats are expanding the capacity for timely case detection at the point of care, while advances in PCR instrumentation and laboratory automation sustain the need for centralized confirmatory testing and genotypic surveillance. At the same time, external forces such as trade policy shifts have made supply chain resilience and sourcing strategy primary determinants of procurement risk and program continuity.

For practitioners and decision-makers, the imperative is clear: align diagnostic selection with clinical pathways and operational realities. This requires a nuanced assessment of test type and technology trade-offs, deliberate sourcing strategies to mitigate external cost pressures, and investment in digital and training infrastructure that reduces implementation friction. Organizations that adopt an integrated approach-combining robust point-of-care screening, laboratory confirmation where needed, and data connectivity-will be best positioned to maintain diagnostic continuity and to support effective clinical and public health responses.

Looking ahead, continued collaboration among diagnostic developers, health systems, and regulatory authorities will be essential to translate innovation into accessible, reliable testing programs. Stakeholders who prioritize supply chain diversification, real-world performance validation, and user-centered product design will accelerate adoption and improve outcomes for patients and communities affected by dengue.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dengue Testing Market, by Test Type

  • 8.1. Antibody Test
    • 8.1.1. Igg Antibody Test
    • 8.1.2. Igm Antibody Test
  • 8.2. Antigen Test
    • 8.2.1. Ns1 Enzyme Linked Immunosorbent Assay
    • 8.2.2. Ns1 Rapid Test
  • 8.3. Molecular Test
    • 8.3.1. Conventional Polymerase Chain Reaction
    • 8.3.2. Real Time Polymerase Chain Reaction

9. Dengue Testing Market, by Technology

  • 9.1. Enzyme Linked Immunosorbent Assay
  • 9.2. Lateral Flow Immunoassay
    • 9.2.1. Colloidal Gold Assay
    • 9.2.2. Fluorescent Immunoassay
  • 9.3. Microarray Technology
  • 9.4. Polymerase Chain Reaction
    • 9.4.1. Conventional Polymerase Chain Reaction
    • 9.4.2. Real Time Polymerase Chain Reaction

10. Dengue Testing Market, by End User

  • 10.1. Clinics
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Dengue Testing Market, by Product Type

  • 11.1. Instruments
    • 11.1.1. Readers
    • 11.1.2. Thermal Cyclers
  • 11.2. Software Solutions
  • 11.3. Test Kits

12. Dengue Testing Market, by Setting

  • 12.1. Central Laboratory
  • 12.2. Point Of Care

13. Dengue Testing Market, by Sample Type

  • 13.1. Plasma
  • 13.2. Serum
  • 13.3. Whole Blood

14. Dengue Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Dengue Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Dengue Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Dengue Testing Market

18. China Dengue Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Alpine Biomedicals Pvt Ltd.
  • 19.7. Bio-Rad Laboratories, Inc.
  • 19.8. Chembio Diagnostics, Inc.
  • 19.9. Danaher Corporation
  • 19.10. F. Hoffmann-La Roche Ltd.
  • 19.11. Meridian Bioscience, Inc.
  • 19.12. MNP Meditech Pvt. Ltd.
  • 19.13. QIAGEN N.V.
  • 19.14. Siemens Healthineers AG
  • 19.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DENGUE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DENGUE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS DENGUE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL DENGUE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GCC DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 229. GCC DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 230. GCC DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 231. GCC DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. GCC DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 238. GCC DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. G7 DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 268. G7 DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 269. G7 DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 270. G7 DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 272. G7 DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 273. G7 DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. G7 DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. G7 DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. G7 DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 277. G7 DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. NATO DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. NATO DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 281. NATO DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 282. NATO DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 283. NATO DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. NATO DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 285. NATO DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 286. NATO DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. NATO DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 290. NATO DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)